NEW YORK, Sept 17 (Reuters) - Hedge fund Irenic Capital

Management on Tuesday urged Kinaxis ( KXSCF ) to see who may want

to buy the Canadian software company and warned its board

against making "reactive decisions" and taking "half measures."

The board "should initiate a full strategic review including

soliciting interest for a sale for the whole company," Irenic

said in a statement, echoing other investors' private and public

calls for the company to put itself up for sale.

Irenic, run by former Elliott Investment Management and

Indaba Capital Management executives Adam Katz and Andy Dodge,

called Kinaxis ( KXSCF ) a "world-class software asset" that needs to find

a new chief executive officer and head of sales and also needs

to review interest in the company from potential financial and

strategic buyers.

Earlier on Tuesday the supply chain management software

supplier said it had hired Goldman Sachs ( GS ), without disclosing the

purpose. But it also said the board "strongly believes that

execution of its strategic plan is the best path to maximize

shareholder value."

Irenic said Kinaxis' ( KXSCF ) new Executive Chairman Robert Courteau

said there has been inbound interest from financial sponsors,

but the board was currently unwilling to engage them.

"The Board is focused on enhancing value for shareholders,

is fully aware of its fiduciary duties, and will continue to act

accordingly," a Kinaxis ( KXSCF ) spokesperson said.

The spokesperson did not directly respond to a request for

comment on what interest the company has received and how it is

engaging.

Irenic said the board cannot make decisions about the "best

path forward without first considering alternative paths,"

expressing concern the board is not fully examining potential

interest in the company.

Investment firm Daventry Group last week publicly urged

Kinaxis ( KXSCF ) to put itself up for sale, calling it a high quality

asset that many buyers would pay a "healthy premium" to own.

Daventry, together with its affiliates, beneficially owns or

controls approximately 1.4% of the outstanding stock of Kinaxis ( KXSCF ),

which has a market value of about $3.2 billion.